CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Autologous BMMNCs transplantation and educational intervention +1 morecombination
Likely dose
Autologous BMMNCs transplantation and educational intervention 8 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05307536
NCT05307536Phase 2Completed

Autologous Bone Marrow Mononuclear Cell Transplantation Combined With Educational Intervention for Autism Spectrum Disorders (ASD): A Phase 2 Randomised Controlled Trial

Vinmec Research Institute of Stem Cell and Gene Technology·interventional·Posted Apr 1, 2022·Updated Jan 22, 2026

In Brief

A Phase 2 clinical trial evaluating Autologous BMMNCs transplantation and educational intervention and Educational intervention for Autism Spectrum Disorder. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow mononuclear cell infusion combined with educational intervention for children with autism spectrum disorder (ASD). Inclusion criteria: Male/Female patients diagnosed with Autism disorder based on DSM-V scale, the patient is between 3 to 7 years old, a patient has a medium level to server level of autism (CARS score\>=30 to \<50), VARS-2 \>=50, patient's parent or caregiver must have the educational level of high school or above, patient's family has given consent to participate in the study. Exclusion criteria for treatment group: patient above seven years of age and smaller than 3-year old, autistic patients having epilepsy, hydrocephalus with ventricular drain, allergy to anesthetic agents, severe health conditions such as cancer, failure of heart, lung, liver, or kidney, active infections, children with birth defects of the spine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesVietnam
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 1, 2022
Enrollment StartDec 26, 2021
Primary CompletionJun 30, 2023
Study CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.3 years ago

Interventions

Autologous BMMNCs transplantation and educational interventioncombination

Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total. Educational intervention: 6 months based on the Early Start Denver Model

Educational interventioncombination

Educational intervention: 6 months based on the Early Start Denver Model